Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial

To determine the proportion of patients with psoriatic arthritis in the Adalimumab Effectiveness in Psoriatic Arthritis trial achieving minimal disease activity (MDA) and its individual components at 1 or more visits over 144 weeks, identify baseline predictors of MDA achievement, and evaluate the a...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Mease, P, Kavanaugh, A, Coates, L, McInnes, I, Hojnik, M, Zhang, Y, Anderson, J, Dorr, A, Gladman, D
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	BMJ Publishing Group 2017

Gelijkaardige items

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
door: Coates, L, et al.
Gepubliceerd in: (2019)

Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial
door: Kavanaugh, A, et al.
Gepubliceerd in: (2024)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
door: Gladman, DD, et al.
Gepubliceerd in: (2018)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
door: Mease, PJ, et al.
Gepubliceerd in: (2020)

Radiographic efficacy of adalimumab in patients with psoriatic arthritis according to demographics, baseline clinical status, methotrexate use and clinical response: subanalysis of adept
door: Choy, E, et al.
Gepubliceerd in: (2007)

Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study
door: Coates, LC, et al.
Gepubliceerd in: (2021)

Adalimumab treatment with and without methotrexate in patients with moderate to severe psoriatic arthritis: Results from adept
door: Kavanaugh, A, et al.
Gepubliceerd in: (2005)

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
door: Coates, LC, et al.
Gepubliceerd in: (2024)

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity
door: Landewé, R, et al.
Gepubliceerd in: (2019)

Psoriatic arthritis
door: FitzGerald, O, et al.
Gepubliceerd in: (2021)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
door: Ogdie, A, et al.
Gepubliceerd in: (2023)

Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research
door: Désirée van der Heijde, et al.
Gepubliceerd in: (2020-02-01)

Classification and outcome measures for psoriatic arthritis
door: Leung, Y, et al.
Gepubliceerd in: (2018)

Measuring outcomes in psoriatic arthritis
door: Ogdie, A, et al.
Gepubliceerd in: (2020)

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
door: Laura C. Coates, et al.
Gepubliceerd in: (2024-02-01)

Considerations for the definition of remission criteria in psoriatic arthritis
door: Mease, P, et al.
Gepubliceerd in: (2017)

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients
door: Orbai, A-M, et al.
Gepubliceerd in: (2019)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
door: Alexis Ogdie, et al.
Gepubliceerd in: (2023-05-01)

Assessing disease activity in psoriatic arthritis: a literature review
door: Tucker, L, et al.
Gepubliceerd in: (2018)

Classification and Outcome Measures for Psoriatic Arthritis
door: Ying Ying Leung, et al.
Gepubliceerd in: (2018-09-01)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
door: Soriano, ER, et al.
Gepubliceerd in: (2023)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
door: Coates, L, et al.
Gepubliceerd in: (2017)

Residual inflammation in psoriatic arthritis patients in stable minimal disease activity
door: Pierluigi Macchioni, et al.
Gepubliceerd in: (2022-12-01)

Methotrexate in psoriasis and psoriatic arthritis
door: Coates, L, et al.
Gepubliceerd in: (2020)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
door: Helliwell, PS, et al.
Gepubliceerd in: (2022)

Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity
door: Ye, W, et al.
Gepubliceerd in: (2018)

Sustained very low disease activity and remission in psoriatic arthritis patients
door: Lubrano, E, et al.
Gepubliceerd in: (2019)

Association between patient perception of disease status and different components of the Minimal Disease Activity (MDA) criteria in psoriatic arthritis
door: Yazji, SM, et al.
Gepubliceerd in: (2025)

The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
door: Strand, V, et al.
Gepubliceerd in: (2022)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
door: Ennio Lubrano, et al.
Gepubliceerd in: (2019-08-01)

Identification of the Minimal Disease Activity Domains Achieved Based on Different Treatments in Psoriatic Arthritis
door: Silvia Scriffignano, et al.
Gepubliceerd in: (2023-09-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
door: Coates, L, et al.
Gepubliceerd in: (2021)

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity
door: Coates, L, et al.
Gepubliceerd in: (2018)

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity
door: Mease, PJ, et al.
Gepubliceerd in: (2019)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
door: Atul Deodhar, et al.
Gepubliceerd in: (2022-07-01)

Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2‐year results from a multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled phase III study
door: Coates, L, et al.
Gepubliceerd in: (2018)

Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study
door: Rubén Queiro, et al.
Gepubliceerd in: (2017-03-01)

BIOLOGIC THERAPY OF PSORIATIC ARTHRITIS
door: D.D. Gladman
Gepubliceerd in: (2011-09-01)

Duration of Psoriatic Skin Disease as Risk Factor for Subsequent Onset of Psoriatic Arthritis
door: Alexander Egeberg, et al.
Gepubliceerd in: (2018-03-01)

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity
door: Laura C. Coates, et al.
Gepubliceerd in: (2018-08-01)